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Abstract 
We examined in detail the tyrosine phosphorylation f proteins, especially inositol phospholipid-specific phospholipase 
C (PLC) ~/ 2, during actiwttion of respiratory burst of guinea pig polymorphonuclear leukocytes (PMNs) by pervanadate. 
The pervanadate, generated from a combination of H20 2 and orthovanadate, induced concomitantly t rosine phosphoryla- 
tion of 145, 120, 104, 76, 68, 60, 53, 42, 37, 28, and 25 kDa proteins and superoxide anion (0 2) production of PMNs. The 
pretreatment of PMNs with genistein caused an inhibition of tyrosine phosphorylation f these proteins, and also markedly 
depressed 0 2 production. Among the above proteins, a 145 kDa protein was found to be identical with the protein 
recognized by the anti-PLC'y 2 antibody on Western blots. PLC~/ 2 was detected in the cytosol fraction but not in the 
membrane fraction of resting PMNs, whereas it was detected in both cytosol and membrane fractions of pervanadate treated 
PMNs. PLC activity of pervanadate reated PMNs was higher than that of resting cells. In addition, the enzyme activity of 
the cytosol fraction from the former cells was significantly lower than that from the latter cells, whereas the enzyme activity 
of membrane fraction from the former cells was significantly higher than that from the latter cells. These findings suggest 
that the tyrosine residue(s) of PLC~/ 2 is phosphorylated and the enzyme is translocated from the cytosol to membrane 
fractions in PMNs by pervanadate reatment. 
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1. Introduction 
Polymorphonuclear leukocytes (PMNs) play an 
important role in host defence against microbial in- 
fections. Exposure of PIVlNs to a variety of stimuli 
* Corresponding author. Fax: +81 75 5954756. 
results in activation of the respiratory burst, during 
which reactive species uch as superoxide anion (02)  
and hydrogen peroxide (H202) are generated [1,2]. 
These active oxygen species play an important role in 
the bactericidal activity of PMNs [3]. The signaling 
pathway through the activation of inositol phospho- 
lipid-specific phospholipase C (PLC) plays a major 
role in activation of NADPH oxidase that exists in 
the plasma membrane and is able to catalyze the 
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one-electron reduction of molecular oxygen to 02 
during the respiratory burst. That is, the binding of 
agonist o their receptors timulates PLC through the 
activation of guanine nucleotide binding proteins (G- 
proteins) [4]. Diacylglycerol produced by PLC acti- 
vates NADPH oxidase presumably through activating 
protein kinase C (PKC) [5]. 
Recently, Bianchini et al. reported that in HL 60 
cells, vanadates, a tyrosine phosphatase inhibitor, in 
the presence of H202 promote the PLC'¢ 2-mediated 
production of inositol 1,4,5-trisphosphate (IP 3) 
through tyrosine phosphorylation f PLC'y 2 [6]. In 
addition, Dusi et al. reported that in human neu- 
trophils Fc~/ receptor activation by insoluble immune 
complex caused a stimulation of phosphoinositide 
hydrolysis and upon Fc'y receptor activation tyrosine 
phosphorylation f PLC'y 2 with a molecular mass of 
145 kDa occurred [7]. However, the function of the 
phosphorylated PLC~/ 2 in NADPH oxidase activa- 
tion is yet obscure. 
Herein, we examined in detail the tyrosine phos- 
phorylation of PLC ~ 2 during the activation of respi- 
ratory burst of guinea pig PMNs. We used pervana- 
date generated by treatment of orthovanadate with 
H202, since it has been shown to enhance the accu- 
mulation of phosphotyrosine-containing proteins in T 
lymphocytes [8] and RBL-2H3 cells [9]. We show 
here that PLC~ 2 is expressed by guinea pig PMNs 
and is present in the cytosol of the resting cells but 
not in the membrane, and that treatment of PMNs 
with pervanadate r sults in tyrosine phosphorylation 
of PLC~/ 2, and in translocation of the phosphory- 
lated PLC~/ 2 to membrane fractions from the cy- 
tosol. 
2. Materials and methods 
2.1. Materials 
L-t~-[myo-inositol 2- 3 H(N)]Phosphatidylinositol 
(1.0 Ci/mol) was purchased from American Radiola- 
beled Chemicals (St. Louis, MO, USA) Phos- 
phatidylinositol (soybean, ammonium salts), phenyl- 
methylsulfonyl fluoride (PMSF), diisopropyl fluoro- 
phosphate (DFP), benzamidine, cytochrome c (type 
III), catalase, sodium orthovanadate w re from Sigma 
(St. Louis, MO, USA), H20 2 from Wako Pure 
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Chemicals (Osaka, Japan), and genistein was from 
Dojindo (Kumamoto, Japan). Anti-phosphotyrosine 
mouse monoclonal antibody, and anti-PLC~/ 1 and 
-PLC',/ 2 rabbit polyclonal antibodies were purchased 
from Transduction Laboratories (KY, USA) and Santa 
Cruz Biotechnology (CA, USA), respectively. All 
other chemicals used were of reagent grade and were 
obtained commercially. 
2.2. Preparation of PMNs 
Guinea pig PMNs were obtained from casein-in- 
duced peritoneal exudates from female Hartley strain 
guinea pigs as described previously [10]. 
2.3. Preparation of pervanadate 
One ml of 10 mM sodium orthovanadate and 1 ml 
of 0.3 M H202 was mixed and incubated in Krebs- 
Ringer's phosphate buffer (pH 7.0) (KRP) for 1 min 
at 37°C, and then 0.5 ml of catalase solution (2 
mg/ml) was added to decompose the remaining 
H20 2. The solution thus obtained was used as 4 mM 
pervanadate, unless otherwise stated. This solution 
was newly prepared in each case. 
2.4. Stimulation of PMNs with pervanadate 
PMNs (107 cells/ml) were incubated in the pres- 
ence and absence of pervanadate in KRP at 37°C 
with shaking. In the experiment with genistein, PMNs 
(107 cells/ml) were pretreated with genistein (100 
txM) for 5 min at 37°C before the incubation with 
pervanadate. After incubation with pervanadate for 
the duration indicated, cell suspensions were with- 
drawn and analyzed for O 2 production, PLC activ- 
ity, and immunochemical detection of phospho- 
tyrosine proteins and PLC-/ family. 
2.5. Preparation of cytosol and membrane fractions 
After treatment of PMNs with pervanadate for 3 
min, cells were separated by centrifugation (100 × g, 
5 min at 4°C) and were resuspended in ice-cold 
extraction buffer (10 mM Hepes, pH 7.0, containing 
0.32 M sucrose, 0.05% NaN 3, 100 IxM Na3VO 4, 3 
mM EGTA, 5 mM benzamidine, 0.1 mM PMSF, 0.5 
mM DFP, and 5 mM 2-mercaptoethanol). After soni- 
N. Kawakami et al. / Biochimica et Biophysica Acta 1314 (1996) 167-174 169 
cation of the cell suspension, the supernatant and 
precipitation were separated by centrifugation (85 000 
× g, 30 min at 4°C), and the precipitation was resus- 
pended in extraction buffer. The supernatant and 
precipitation thus obtained were used as cytosol and 
membrane fractions, respectively. 
2.6. Of  determination 
0 2 production by PMNs was measured on the 
basis of the reduction of ferricytochrome c by the 
anion produced. In brief, PMN samples (10 6 
cells/ml) were incubal:ed with cytochrome c (50 
IxM) and glucose (5 mM) in KRP with shaking. After 
appropriate incubation, superoxide dismutase (10 
p~g/ml) was added to stop the reaction, and then the 
supernatant was separated by centrifugation. Reduced 
cytochrome c in the supernatant was measured on the 
basis of increase in absorbance at 550 nm, and 0 2 
generation was calculated by using an absorption 
coefficient of 19.1 mM -1 cm -1 at 550 nm [11] for 
the reduction of cytochrome c. 
2.7. PLC activity 
buffer (2% sodium dodecyl sulfate (SDS), 30% glyc- 
erol, 10% 2-mercaptoethanol, 0.01% bromphenol blue 
dye in 0.25 M Tris-HC1, pH 6.8) [14] and were 
heated at 100°C for 3 min, and then were subjected to 
electrophoresis on 4-20% SDS-polyacrylamide g ls, 
electrotransferred to Immobilon (Millipore), blocked 
for 1 h with phosphate-buffered saline containing 
0.1% Tween 20 (TPBS), and then incubated with an 
anti-phosphotyrosine mouse monoclonal antibody 
(1:500) or anti-PLC~ 1 or -PLC',/ 2 rabbit polyclonal 
antibodies (1:500) in PBS containing 3% BSA for 18 
h at 4°C. Blots were washed with TPBS, incubated 
with biotinylated anti-mouse or anti-rabbit IgG (Vec- 
tor, CA, USA) in PBS, washed again with Tris- 
buffered saline, and then visualized with diaminoben- 
zidine and H20 2. For the immunoprecipitation, cy-
tosol fractions obtained from resting and pervanadate 
treated PMNs as described above were immunopre- 
cipitated with anti-phosphotyrosine antibody conju- 
gated with agarose (Transduction Laboratories). The 
precipitates collected by brief centrifugation were 
subjected to electrophoresis and then immunoblotting 
by using anti-phosphotyrosine antibody or anti-PLC',/ 
2 antibody as described above. 
The PLC activity was measured according to the 
method described previously by using phosphatidyli- 
nositol as a substrate [12]. In brief, the reaction 
mixtures contained 280 ~M phosphatidylinositol, 
30,000 dpm of L-Ce-[myo-inositol 2-3H(N)]phos - 
phatidylinositol, 1 mg/ml  sodium deoxycholate, 1.5 
mM CaC12, 50 mM Hepes (pH 7.0), and enzyme 
fractions. After incubation at 37°C, the reaction was 
stopped with 1 ml of chloroform/methanol/con- 
centrated HC1 (50:50:0.3), followed by the addition 
of 0.3 ml of 1M HC1 containing 5 mM EGTA. After 
centrifugation for 10 rnin at 3000 × g, a 700-txl 
aliquot of the supernatant was removed for liquid 
scintilation counting. PLC activity was defined as 
nmol of inositolphosphate released from phos- 
phatidylinositol. The protein concentration was mea- 
sured by the method of Lowry et al. [13]. 
2.8. Immunochemical detection of phosphotyrosine 
proteins and the PLCy family 
Each cell suspension, whole extract, cytosol frac- 
tion or membrane fraction, was mixed 1:1 with lysis 
2.9. Statistical evaluation 
The results are given as mean + standard error 
(S.E.) values. Statistical significance was determined 
using ANOVA and Dunnett's two-tailed test. Analy- 
sis was performed using STATVIEW II software 
(Abcus Concepts) and a Macintosh personal com- 
puter (Apple Computer). 
3. Results 
3.1. Of  production and tyrosine phosphorylation of 
proteins in pervanadate treated PMNs 
In guinea pig PMNs incubated with pervanadate, 
O~- production observed was dependent on the reac- 
tion time, especially, O~- production was rapidly 
increased at the incubation step from 2 to 3 min (Fig. 
1A). The incubation of PMNs with pervanadate r - 
suited in the tyrosine phosphorylation of 145 kDa 
protein and other many proteins including at least 
120, 104, 76, 68, 60, 53, 42, 37, 28, and 25 kDa 
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Fig. 1. O 2 production and phosphotyrosine proteins of PMNs 
treated with pervanadate. To prepare the vanadate or pervanadate 
solution for incubation with PMNs, vanadate alone, H202 alone 
or the combination of vanadate and H202 was incubated with 
KRP at 37°C for 1 min, and then catalase was added to the 
incubated solution as described in Section 2. PMNs (107 cells/ml) 
were incubated at 37°C for the indicated times, and then the cell 
suspensions were withdrawn and analyzed for O~- production 
(A) and phosphotyrosine proteins (B) as described in Section 2. 
sine phosphorylation of the above many proteins 
including the 145 kDa protein was inhibited by genis- 
tein (Fig. 2B). 
A 42 kDa protein was also tyrosine phosphorylated 
by stimuli such as N-formyl-methionyl-leucyl- 
phenylalanine (FMLP) and phorbor myristate acetate 
(PMA), whereas tyrosine phosphorylation of other 
proteins including 145 kDa protein was not induced 
by PMA and FMLP (data not shown). 
3.2. Identification of a 145 kDa phosphotyrosine 
protein as the PLCT 2 
It has been previously reported in human PMNs 
that upon Fcy receptor activation tyrosine phospho- 
rylation of PLCy 2 with a molecular mass of 145 
kDa occurred [7]. We tested the resting and pervana- 
date treated cell homogenates with an anti-PLCy 2 
antibody. The 145 kDa protein which was phosphory- 
lated by pervanadate treatment of PMNs was found 
to be identical with the protein recognized by this 
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proteins on the step inducing more rapid O 2 release 
(Fig. 1B). To know the relationship between O 2 
release and tyrosine phosphorylation of  these pro- 
teins, we studied the effect of  genistein, a tyrosine 
kinase inhibitor. As shown in Fig. 2A, O 2 produc- 
tion was depressed to approximately 40% by the 
pretreatment of  PMNs  with genistein (100 ~M) .  
Gesistein was not toxic to PMNs in this experiment 
as the cell viability estimated by trypan blue staining 
was not changed by 100 ~M genistein treatment 
(data not shown). Under the same conditions, tyro- 
Fig. 2. Effect of genistein-pretreatment on 0 2 production and 
tyrosine phosphorylation of proteins of PMNs by pervanadate 
treatment. PMNs (107 cells/ml) were preincubated in the pres- 
ence and absence of genistein (100 ~M) in KRP for 5 min at 
37°C, and then further incubated with pervanadate (100 p~M) for 
3 min at 37°C. Then, the cell suspensions were withdrawn and 
analyzed for O~ production (A) and phosphotyrosine proteins 
(B) as described in Section 2. Bars show the S.E. (n = 6). 
Numbers below the columns show the samples of PMNs without 
genistein and pervanadate (resting PMNs)(1), PMNs with per- 
vanadate but without genistein (2), and PMNs with both genistein 
and pervanadate (3). * Significantly different from that of non- 
treated PMNs with genistein (P < 0.01). 
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Fig. 3. Immunodetection of phosphotyrosine proteins and PLC~ 
2 using specific antibodies. PMNs (10 7 cells/ml) were preincu- 
bated in the presence and absence of genistein (100 IxM) in KRP 
at 37°C for 5 min, and then further incubated with or without 
pervanadate (100 ~M) for 3 min. After incubation, cells were 
separated, resuspended in the extraction buffer, and sonicated to
obtain whole extracts. From the whole extract of the above cell 
preparations, the cytosol and membrane fractions were prepared, 
and each fraction and whole extract in lysis buffer was subjected 
to Westem blot analysis, a,~ described in Section 2. Mouse 
anti-phosphotyrosine a tibody and rabbit anti-PLC'v 2 antibody 
were used to detect the phosphotyrosine proteins and PLC-y 2, 
respectively. (A and B) Whole extract (a), cytosol fraction (b), 
and membrane (c) fractions from resting (lane 1), pervanadate- 
treated (lane 2), and genistein--pretreated th npervanadate-treated 
(lane 3) PMNs have been subjected to electrophoresis and im- 
munoblotted with anti-phosphotyrosine a tibody (A) or with 
anti-PLC-,/ 2 antibody (B) as described in Section 2. (C) Materi- 
als immunoprecipitated with anti-phosphotyrosine antibody from 
cytosol fraction of resting (lane 1) and pervanadate-treated (lane 
2) PMNs, were subjected to electrophoresis, electroblotted and 
probed with anti-phosphotyrosine a tibody (a) or anti-PLC-y 2 
antibody (b) as described in Section 2. 
anti-PLC'y 2 antibody (lane 2 of Fig. 3A and B). To 
confirm the identity of this protein as PLC~/ 2, 
cytosol fraction from resting and pervanadate reated 
PMNs were immunoprecipitated with anti-phospho- 
tyrosine antibody conjugated with agarose, and then 
immunoblotted with the same anti-phosphotyrosine 
antibody (Fig. 3C-a) or with anti-PLC'y 2 antibody 
(Fig. 3C-b). Anti-phosphotyrosine antibody precipi- 
tated from the cytosol fraction of pervanadate reated 
PMNs a 145 kDa protein. The protein was found to 
be positive on blots by both anti-phosphotyrosine 
antibody and anti-PLC~/ 2 antibody. The above find- 
ings were not observed with the cytosol fraction of 
the resting cells. These findings strongly suggest hat 
one of the 145 kDa phosphoproteins that appeared 
during respiratory burst of PMNs by pervanadate 
treatment is the PLC~/ 2. 
3.3. Translocation of PLCT 2 in pervanadate treated 
PMNs 
To examine the distribution of PLC',/ 2 in guinea 
pig PMNs, Western blotting using anti-PLC~/ 2 and 
anti-phosphotyrosine antibodies was performed on 
cytosol and membrane fractions obtained from rest- 
ing, pervanadate treated, and genistein-pretreatment 
followed by pervanadate reated PMNs. As shown in 
lane 1 of Fig. 3B-b and -c, PLC~/ 2 was detected in 
the cytosol fraction of resting PMNs, but not in the 
membrane fraction. However, after treatment of 
PMNs with pervanadate, PLC~/2 was detected in the 
membrane fraction (lane 2 of Fig. 3B-c), and the 
amount of PLC~ 2 in the cytosol fraction of the 
pervanadate reated cells was less than that of resting 
cells (lanes 1 and 2 of Fig. 3B-b). A 145 kDa 
phosphotyrosine protein was detected in both cytosol 
and membrane fractions of pervanadate reated PMNs 
(lane 2 of Fig. 3A-b and -c). In addition, by the 
pretreatment of PMNs with genistein, the amount of 
tyrosine phosphorylated 145 kDa protein and PLC~/ 
2 in the membrane fractions was lower than that in 
the membrane fraction of PMNs without genistein- 
pretreatment (lanes 2 and 3 of Fig. 3A-c and Fig. 
3B-c). These findings suggest hat PLC'y 2 exists in 
the cytosol fraction of resting cells and upon phos- 
phorylation of PLC-y 2 translocation of the phospho- 
rylated enzyme from cytosol to membrane occurs. 
We also carried out Western blots using the anti- 
PLC'y 1 antibody on the cytosol and membrane 
fractions of both resting and pervanadate treated 
PMNs. PLC~/ 1 was also detected only in the cytosol 
fraction of resting cells, but much less than the 
amount of PLC~/ 2. With PLC~/ 1, we could not 
detect the translocation upon pervanadate treatment 
(data not shown). 
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3.4. PLC activity of pervanadate treated PMNs 
Upon pervanadate treatment of guinea pig PMNs 
as described above, phosphorylation of PLC'y 2 was 
caused and then translocation of the phosphorylated 
enzyme from the cytosol to membrane occurred. 
Phosphorylation of PLC-/ 2 in human PMNs and HL 
60 cells results in promotion of phosphatidylinositide 
turnover [6,7]. Thus, we determined the total PLC 
activity of resting and pervanadate reated PMNs. 
As shown in Table 1, total PLC activity was found 
to be increased by pervanadate treatment of PMNs, 
and this increase was reduced by pretreatment of 
PMNs with genistein. Then, we compared the total 
PLC activity of the cytosol and membrane fractions 
obtained from the above three types of PMNs, i.e., 
resting, pervanadate treated, and genistein-pretreat- 
ment followed by pervanadate reated cells (Table 1). 
PLC activity of the cytosol fraction was reduced 
largely by pervanadate treatment, and this reduction 
was inhibited partly by pretreatment of PMNs with 
genistein. On the other hand, PLC activity of mem- 
brane fraction was increased significantly by per- 
vanadate treatment, and this increase was inhibited by 
pretreatment of PMNs with genistein. The above 
observed distribution of PLC activity in the cytosol 
and membrane fractions of the three types of cells 
was similar to that of PLC'y 2 (Fig. 3B-b and -c). 
These findings strongly support he view that PLC-/ 
2 in the cytosol is transferred to the membrane from 
cytosol through tyrosine phosphorylation of the en- 
zyme. 
4.  D iscuss ion  
In the present experiments, we examined in detail 
the tyrosine phosphorylation of proteins, especially 
PLC~/ 2, during activation of respiratory burst of 
guinea pig PMNs. When PMNs were incubated with 
pervanadate, activation of NADPH oxidase was ob- 
served at the stage that tyrosine phosphorylation of
many proteins (145, 120, 104, 76, 68, 60, 53, 42, 37, 
28, and 25 kDa) occurred rapidly. Tyrosine phospho- 
rylation of these proteins was largely inhibited by 
pretreatment of PMNs with genistein, a tyrosine ki- 
nase inhibitor. Under the same conditions, activation 
of NADPH oxidase of PMNs was similary depressed 
significantly. It is obscure at present which protein(s) 
is actually involved in activation of NADPH oxidase. 
Among the proteins that tyrosine phosphorylation 
was caused by pervanadate treatment of PMNs and 
Table 1 
PLC activity of whole extract, cytosol fraction and membrane fraction 
PLC activity (nmole/min/mg protein) 
None ~ Pervanadate b Genistein + pervanadate c 
Whole extract 12.744 +__ 0.628 15.236 ___ 0.828 13.000 _+0.557 
I - -  d I I ¢ - - 1  
Cytosol fraction 11.357 +_0.471 6.808 _+ 0.339 9.145 ___ 0.535 
I f ~ I g . . . . .  I 
Membrane fraction 4.305_+ 0.729 5.967_+ 0.732 4.733 ___ 0.839 
t h , ,  I I i I 
PMNs (10 7 cells/ml) were pretreated with and without genistein (100 IxM) for 5 min at 37°C, and then stimulated with pervanadate (100 
ixM) for 3 min at 37°C. After incubation, cells were separated, resuspended, and sonicated. The sonicated solution was used as the whole 
extract. Preparation fthe cytosol and the membrane fractions from the above whole xtract and assay for PLC activity were as described 
in Section 2. Data are expressed as mean + S.E. of four to twelve experiments. 
a None: resting PMNs, b Pervanadate: pervanadate-stimulated PMNs, c Genistein +pervanadate: PMNs pretreated with genistein before 
pervanadate stimulation. 
Significantly different: d, P < 0.05; e, P < 0.05; f, P < 0.001; g, P < 0.005; h, P < 0.001; and i, P < 0.01. 
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its phosphorylation was inhibited by genistein, a 145 
kDa protein was identified as PLC~/ 2 on Western 
blots using anti-PLC~ 2, antibody, and PLC~/ 2 was 
found to be expressed as a major component of the 
PLC'¢ family in the cytosol fraction of resting cells. 
There is a possibility that the 145 kDa protein phos- 
phorylated under our experimental conditions is not 
only PLC ~ 2, as other tyrosine phosphorylated pro- 
teins of this size unrelated to PLC~ 2 appear in 
stimulated neutrophils [15,16]. Upon treatment of 
PMNs with pervanadate, tyrosine phosphorylation f 
PLC ~ 2 was induced and the phosphorylated nzyme 
was translocated from the cytosol fraction to the 
membrane fraction. The translocation of PLC ~ 2 was 
inhibited by pretreatment of PMNs with genistein. 
Furthermore, PLC activity of pervanadate treated 
PMNs was higher than that of resting cells. Compari- 
son of the PLC activity of cytosol and membrane 
fractions obtained from resting PMNs with that of 
pervanadate reated PMNs revealed that the enzyme 
activity of cytosol fraction from the latter cells was 
significantly lower than that from the former cells, 
whereas that of the membrane fraction obtained from 
the latter cells was significantly higher than that from 
the former cells. Only a fraction of the PLC activity 
that disappeared from the cytosol was recovered in 
the membrane, suggesting that some PLC in the 
cytosol might be inactivated by H20 2 or O~- gener- 
ated in pervanadate treated PMNs. The change of 
PLC activity in the cytosol and membrane fractions 
was similar to the change of PLC'y 2 protein levels 
(Fig. 3B-b and -c). These findings strongly support 
the view that PLC'y 2 is translocated from the cytosol 
to membrane through tyrosine phosphorylation f the 
enzyme. These findings suggest hat upon treatment 
of PMNs with pervanadate PLC~/ 2 present in the 
cytosol is phosphorylated at tyrosine residue(s) and 
then associates to the membrane fraction, resulting in 
a stimulation of second messanger p oduction such as 
diglyceride and inositol phosphates from the plasma 
membrane. 
Dusi et al. recently reported that in human PMNs 
upon Fc~/ receptor activation by insoluble immune 
complex PLC'¢ 2 is phosphorylated at the tyrosine 
residue and phosphoinositide hydrolysis is stimulated 
[7]. Bianchini et al. haw. ~also reported that in HL 60 
cells vanadate in the presence of H202 promotes the 
PLC',/ 2-mediated production of IP 3 through tyrosine 
phosphorylation of PLC~ 2 [6]. In addition, Tod- 
derud et al. reported that epidermal growth factor 
treatment of A-431 epidermoid carcinoma cells elicits 
a redistribution of PLC~/ 1 from a predominantly 
cytosol ocalization to membrane fractions, and that 
the amount of PLC~/ 1 associated with membrane 
fractions coincides with the stoichimetry of growth 
factor-induced tyrosine phosphorylation f PLC'y 1 
[17]. Therefore, our findings may suggest hat the 
membranous a sociation of PLC',/ 2 is a significant 
event in signal transduction i  PMNs functions. How- 
ever, the exact physiological role of PLC~/ 2 in 
respiratory burst of PMNs remains obscure. 
The PLC[3 family is regulated by G-proteins 
[18,19], while the PLC',/ family is regulated through 
tyrosine phosphorylation by tyrosine kinase [20-22]. 
It is generally accepted that binding of agonist to 
their receptors timulates PLC, possibly PLCI3 fam- 
ily, through the activation of G-proteins in PMNs [4]. 
The PLC hydrolyzes phosphatidylinositol 4,5-bis- 
phosphate into 1,2-diacylglycerol, a PKC activator, 
and IP3, a calcium ion mobilizer. The activation of 
PKC leads to activation of NADPH oxidase. FMLP 
stimulates PMNs to activate NADPH oxidase through 
the receptor mediated signaling pathways [23], while 
PMA activates directly the respiratory burst in PMNs 
[24,25]. However, PKC inhibitors failed to inhibit 
most of the responses of PMNs by FMLP [26], and 
the presence of distinct pathways for FMLP- and 
PMA-induced 0 2 generation of PMNs has been 
suggested [27]. We also observed that 0 2 production 
of PMNs by pervanadate reatment was not affected 
by the pretreatment of PMNs with staurosporine, 
even at sufficient concentrations of staurosporine 
which can inhibit significantly O~- production by 
PMA (unpublished ata). Therefore, the activation 
routes of NADPH oxidase by pervanadate reatment 
of PMNs may be a PKC- independent pathway 
through phosphorylation f PLC',/ 2. 
The present study showed that tyrosine residue(s) 
of PLC y 2 was phosphorylated and the isozyme was 
translocated from cytosol to membrane in PMNs by 
pervanadate reatment. This is the first report on such 
phenomena with PMNs. However, further investiga- 
tions are required to clarify precisely where tyrosine- 
phosphorylated and translocated PLC ~ 2 is involved 
in the activation of NADPH oxidase and to elucidate 
the role of the tyrosine phosphatase, which is inhib- 
174 N. Kawakami et al. / Biochimica et Biophysica Acta 1314 (1996) 167-174 
ited by vanadate and dephosphorylates phosphoryla- 
tion of tyrosine residues of PLC~/ 2. 
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